<DOC>
	<DOCNO>NCT01207089</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics pharmacodynamics AZD8329 follow multiple ascend dose administration overweight obese otherwise healthy male subject .</brief_summary>
	<brief_title>To Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics Oral Administration AZD8329</brief_title>
	<detailed_description>A Phase I , Single Centre , Single-blind , Randomised , Placebo-controlled , Parallel-group Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics oral AZD8329 Administration Multiple Ascending Doses Abdominally Obese otherwise Healthy Male Subjects</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>Have body mass index ( BMI ) 27 35 kg/m2 waist circumference great equal 102cm . Provision sign date , write informed consent prior study specific procedure Healthy male subject age =20 =50 year suitable vein cannulation repeat venepuncture History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate . Fasting serum ( S ) glucose =7.0 mmol/L nonfasting Sglucose =11.1 mmol/L screen . Any eating disorder actively attempt loose weight within 3 month prior enrolment</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>healthy</keyword>
	<keyword>overweight</keyword>
	<keyword>obese</keyword>
</DOC>